Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Group 1: Company Performance - Johnson & Johnson (JNJ) closed at $167.28, with a +1.37% increase, outperforming the S&P 500's loss of 1.76% [1] - Over the previous month, JNJ shares gained 8.46%, significantly surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26% [1] Group 2: Upcoming Earnings - The upcoming earnings disclosure is anticipated to show an EPS of $2.59, reflecting a 4.43% decline compared to the same quarter last year [2] - Revenue is expected to be $21.66 billion, indicating a 1.29% increase from the same quarter last year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $10.58 per share, with a revenue estimate of $90.03 billion, representing changes of +6.01% and +1.36% respectively from the previous year [3] Group 4: Analyst Forecast Revisions - Recent revisions to analyst forecasts are crucial as they indicate changing business trends, with positive revisions reflecting analysts' confidence in the company's performance [4] Group 5: Zacks Rank and Stock Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks JNJ at 3 (Hold) [6] - The Zacks Consensus EPS estimate has increased by 0.03% in the past month [6] Group 6: Valuation Metrics - JNJ has a Forward P/E ratio of 15.59, which is higher than the industry average of 12.91 [7] - The PEG ratio for JNJ stands at 2.65, compared to the average PEG ratio of 1.47 for Large Cap Pharmaceuticals [7] Group 7: Industry Ranking - The Large Cap Pharmaceuticals industry is currently ranked 196 in the Zacks Industry Rank, placing it in the bottom 22% of over 250 industries [8]